Subject areaBiologyMore specific subject areaInflammationType of dataGraphs, figuresHow data was acquiredqRT-PCR array, QuantStudio 3 (Life Technologies)Data formatAnalyzedExperimental factorsBNL CL.2 cells treated with resistin in the presence or absence of CAP1 siRNA transfectionExperimental featuresUntransfected or CAP1 siRNA-transfected BNL CL.2 cells were treated with resistin, and mRNA expression levels of 84 genes related to insulin resistance were measured by using qRT-PCR array.Data source locationNew York, New York, USAData accessibilityData is with this articleRelated research articleLee S, Lee H--C, Kwon Y--W, Lee SE, Cho Y, Kim J et al. Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes. Cell Metab. 2014 Mar 4; 19(3):484--97**Value of the data**•The role of murine resistin in mediating insulin sensitivity of the peripheral tissues and adenylyl cyclase-associated protein 1 (CAP1) as potential resistin receptor is not yet well understood.•We used BNL CL.2 mouse liver cells that were treated with resistin in the presence or absence of CAP1 siRNA transfection.•We found that resistin modulates gene expression of several genes related to insulin resistance, and the effect of some of these genes is modulated by CAP1.

1. Data {#sec1}
=======

1.1. Optimization of CAP1 siRNA transfections {#sec1.1}
---------------------------------------------

Our optimization experiments (data not shown) demonstrated that there was no statistically significant difference in CAP1 mRNA expression levels between untransfected and siRNA negative control-transfected cells. There was a significant decrease (86%) in CAP1 siRNA levels in CAP1 siRNA-transfected cells, compared to untransfected controls. There was no statistically significant difference in the cell viability between all of the treatment conditions.

### 1.2. Effect of resistin on the expression of genes related to insulin resistance in BNL CL.2 cells {#sec1.2}

Using quantitative RT-PCR array, we measured the expression levels of 84 key genes involved in the mechanisms behind type 2 *diabetes mellitus* (T2DM) in adipose tissue (the full list of genes is presented in [Table 1](#tbl1){ref-type="table"}, and list of genes grouped by function is provided in [Table 2](#tbl2){ref-type="table"}) in BNL CL.2 cells in the presence or absence of resistin (25 ng/ml for 24 hours) ([Fig. 1](#fig1){ref-type="fig"}).Table 1**List of genes examined.** Table list of all genes measured by the PCR array, including the NCBI reference sequence database (RefSeq), gene abbreviations, full names and/or synonyms.Table 1RefSeqAbbreviationFull NameNM_133360AcacaAcetyl-Coenzyme A carboxylase alphaNM_133904AcacbAcetyl-Coenzyme A carboxylase betaNM_007981Acsl1Acyl-CoA synthetase long-chain family member 1NM_019477Acsl4Acyl-CoA synthetase long-chain family member 4NM_009605AdipoqAdiponectin, C1Q and collagen domain containingNM_028320Adipor1Adiponectin receptor 1NM_197985Adipor2Adiponectin receptor 2NM_011785Akt3Thymoma viral proto-oncogene 3NM_009662Alox5Arachidonate 5-lipoxygenaseNM_009696ApoeApolipoprotein ENM_009807Casp1Caspase 1NM_011331Ccl12Chemokine (C--C motif) ligand 12NM_009916Ccr4Chemokine (C--C motif) receptor 4NM_009917Ccr5Chemokine (C--C motif) receptor 5NM_009835Ccr6Chemokine (C--C motif) receptor 6NM_007643Cd36CD36 antigenNM_007648Cd3eCD3 antigen, epsilon polypeptideNM_007678CebpaCCAAT/enhancer binding protein (C/EBP), alphaNM_007700ChukConserved helix-loop-helix ubiquitous kinaseNM_013493CnbpCellular nucleic acid binding proteinNM_016715Crlf2Cytokine receptor-like factor 2NM_026444CsCitrate synthaseNM_009910Cxcr3Chemokine (C-X-C motif) receptor 3NM_009911Cxcr4Chemokine (C-X-C motif) receptor 4NM_010130Adgre1EGF-like module containing, mucin-like, hormone receptor-like sequence 1NM_024406Fabp4Fatty acid binding protein 4, adipocyteNM_007988FasnFatty acid synthaseNM_030678Gys1Glycogen synthase 1, muscleNM_013820Hk2Hexokinase 2NM_008337IfngInterferon gammaNM_010512Igf1Insulin-like growth factor 1NM_010513Igf1rInsulin-like growth factor I receptorNM_010546IkbkbInhibitor of kappaB kinase betaNM_008365Il18r1Interleukin 18 receptor 1NM_008361Il1bInterleukin 1 betaNM_008362Il1r1Interleukin 1 receptor, type INM_144548Il23rInterleukin 23 receptorNM_001314054Il6Interleukin 6NM_010568InsrInsulin receptorNM_010570Irs1Insulin receptor substrate 1NM_001081212Irs2Insulin receptor substrate 2NM_008413Jak2Janus kinase 2NM_008493LepLeptinNM_010704LeprLeptin receptorNM_010719LipeLipase, hormone sensitiveNM_008509LplLipoprotein lipaseNM_008517Lta4hLeukotriene A4 hydrolaseNM_008927Map2k1Mitogen-activated protein kinase kinase 1NM_011952Mapk3Mitogen-activated protein kinase 3NM_016961Mapk9Mitogen-activated protein kinase 9NM_020009MtorMechanistic target of rapamycin (serine/threonine kinase)NM_021524NamptNicotinamide phosphoribosyltransferaseNM_010907NfkbiaNuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alphaNM_145827Nlrp3NLR family, pyrin domain containing 3NM_138648Olr1Oxidized low density lipoprotein (lectin-like) receptor 1NM_011044Pck1Phosphoenolpyruvate carboxykinase 1, cytosolicNM_011055Pde3bPhosphodiesterase 3B, cGMP-inhibitedNM_133667Pdk2Pyruvate dehydrogenase kinase, isoenzyme 2NM_008814Pdx1Pancreatic and duodenal homeobox 1NM_008839Pik3caPhosphatidylinositol 3-kinase, catalytic, alpha polypeptideNM_001024955Pik3r1Phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)NM_011144PparaPeroxisome proliferator activated receptor alphaNM_011146PpargPeroxisome proliferator activated receptor gammaNM_008904Ppargc1aPeroxisome proliferative activated receptor, gamma, coactivator 1 alphaNM_011201Ptpn1Protein tyrosine phosphatase, non-receptor type 1NM_023258PycardPYD and CARD domain containingNM_011255Rbp4Retinol binding protein 4, plasmaNM_009045RelaV-rel reticuloendotheliosis viral oncogene homolog A (avian)NM_022984RetnResistinNM_028259Rps6kb1Ribosomal protein S6 kinase, polypeptide 1NM_009127Scd1Stearoyl-Coenzyme A desaturase 1NM_008871Serpine1Serine (or cysteine) peptidase inhibitor, clade E, member 1NM_011977Slc27a1Solute carrier family 27 (fatty acid transporter), member 1NM_009204Slc2a4Solute carrier family 2 (facilitated glucose transporter), member 4NM_007707Socs3Suppressor of cytokine signaling 3NM_011480Srebf1Sterol regulatory element binding transcription factor 1NM_033218Srebf2Sterol regulatory element binding factor 2NM_011486Stat3Signal transducer and activator of transcription 3NM_021297Tlr4Toll-like receptor 4NM_013693TnfTumor necrosis factorNM_011609Tnfrsf1aTumor necrosis factor receptor superfamily, member 1aNM_011610Tnfrsf1bTumor necrosis factor receptor superfamily, member 1bNM_009463Ucp1Uncoupling protein 1 (mitochondrial, proton carrier)NM_013703VldlrVery low density lipoprotein receptorNM_007393ActbActin, betaNM_009735B2mBeta-2 microglobulinNM_010368GusbGlucuronidase, betaNM_008084GapdhGlyceraldehyde-3-phosphate dehydrogenaseNM_008302Hsp90ab1Heat shock protein 90 alpha (cytosolic), class B member 1SA_00106MGDCMouse Genomic DNA ContaminationSA_00104RTCReverse Transcription ControlSA_00104RTCReverse Transcription ControlSA_00104RTCReverse Transcription ControlSA_00103PPCPositive PCR ControlSA_00103PPCPositive PCR ControlSA_00103PPCPositive PCR ControlTable 2**Genes by function.** Table lists all of the genes examined, separated by function.Table 2FunctionGeneInsulin signalingAkt3Gys1Igf1Igf1rIkbkb(IKK2)InsrIrs1Irs2Map2k1(Mek1)Mapk3(Erk1)Mapk9(Jnk2)MtorPde3bPik3ca(p110-alpha)Pik3r1(PI3KA, p85alpha)Ppargc1a(Pgc-1alpha, Ppargc1)Ptpn1(Ptp1b, Ptp)Rps6kb1Slc2a4(Glut4)Socs3Srebf1Non-insulin dependent diabetes mellitusAdipoq(Acrp30)Hk2Ikbkb(IKKbeta, IKK2)InsrIrs1Irs2Mapk3(Erk1)Mapk9(Jnk2)MtorPdx1(Ipf1)Pik3ca(p110-alpha)Pik3r1(PI3KA, p85-alpha)Slc2a4(Glut4)Socs3TnfAdipokine signaling*Adipokines*Adipoq(Acrp30)Il6LepNamptRetnSerpine1(PAI-1)Tnf*Receptors & transporters*Adipor1Adipor2Cd36LeprSlc2a4(Glut4)Tnfrsf1a(Tnfr1)Tnfrsf1b*Signaling downstream of adipokines*Akt3Chuk(Ikbka, Ikka)Ikbkb(IKK2)Irs1Irs2Jak2Mapk9(Jnk2)MtorNfkbia(Iκb-alpha, Mad3)PparaPpargc1a(Ppargc1)RelaSocs3Stat3Innate immunityCasp1(ICE)Chuk(Ikbka, Ikka)Ikbkb(IKK2)Irs1Irs2Nlrp3Nfkbia(Iκb-alpha, Mad3)Pycard(Tms1, Asc)RelaTlr4InflammationAlox5Casp1(Ice)Ccl12(MCP-5, Scya12)Ccr4Ccr5Chuk(Ikbka, Ikka)Cxcr4IfngIkbkb(IKK2)Il1bIl23rIl6Lta4hNlrp3Olr1Pycard(Tms1, Asc)RelaTnfTnfrsf1a(Tnfr1)Tnfrsf1bApoptosisPpargSerpine1PAI-1)TnfCasp1(Ice)Ikbkb(IKK2)Irs2Mapk9(Jnk2)Nfkbia(Iκb-alpha, Mad3)Nlrp3Pycard(Tms1, Asc)RelaTnfrsf1a (Tnfr1)Jak2Pik3ca (p110-alpha)Socs3Rps6kb1Tnfrsf1bMetabolic pathways*Carbohydrate metabolism*CsGys1Hk2Pck1Pdk2*Lipid metabolism*AcacaAcacbAcsl1Acsl4ApoeCebpaCnbpFabp4FasnLeprLipeLplPparaPpargPpargc1a(Ppargc1)Scd1Srebf1Srebf2*Metabolite transport*ApoeCd36Fabp4Rbp4Slc2a4(Glut4)Slc27a1Ucp1VldlrInfiltrating leukocyte markers*Macrophages*Ccr5Cxcr4Adgre1*Th1 cells*Ccr5Cd3eCxcr3Il18r1*Th2 cells*Ccr4Cd3eCrlf2 (Tslpr)Il1r1*Th17 cells*Ccr6Cd3eIl23rFig. 1**Gene expression--clustergram.** Clustergram of the entire dataset displaying a heat map with dendrograms indicating co-regulated genes across groups or individual samples.Fig. 1

Resistin treatment resulted in statistically significant change in the expression of 6 genes ([Table 3](#tbl3){ref-type="table"}). Of these genes, 3 were significantly upregulated (Apoe, Cs, and Pik3rl) and 3 downregulated (Casp1, Rbp4, and Rps6kb1) ([Fig. 2](#fig2){ref-type="fig"}A). Functionally, these genes participate in metabolic pathways (Apoe, Cs, and Rbp4), insulin signaling (Pik3r1 and Rps6kb1), T2DM (Pik3r1), innate immunity (Casp1), inflammation (Casp1), and apoptosis (Casp1 and Rps6kb1) ([Fig. 2](#fig2){ref-type="fig"}B).Table 3**Fold regulation of gene expression (treatment *vs.* control).** Fold change of gene expression of each treatment *vs.* control. p values \<= 0.05 are marked in bold.Table 3GeneResistinCAP1 siRNACAP1 siRNA + ResistinFold Regulationp-valueFold Regulationp-valueFold Regulationp-valueAcaca−1.140.169661−1.220.2906321.000.878421Acacb1.010.9067481.090.4389271.060.643704Acsl11.020.7240411.44**0.000491**1.36**0.018940**Acsl41.040.5420861.080.3568231.120.206335Adipoq−1.100.1733961.32**0.041017**1.150.401499Adipor1−1.040.3292311.020.6406831.060.146953Adipor21.130.1139311.17**0.028059**1.34**0.016324**Akt31.070.1268581.030.2561811.010.782413Alox51.420.3640081.750.0994391.510.263775Apoe1.55**0.022577**1.29**0.046392**−1.020.812274Casp1−1.89**0.003612**1.410.2244871.240.252274Ccl121.220.3061901.510.0994501.330.142705Ccr41.000.9257981.52**0.021117**1.170.271836Ccr5−1.050.6124331.270.3575041.070.791426Ccr6−1.070.5700251.140.3586161.070.661161Cd36−1.080.9794981.170.4806361.740.080825Cd3e1.300.3670861.550.1222201.280.416990Cebpa−1.010.5545661.160.0453971.050.407643Chuk−1.000.9233921.070.2309931.060.155313Cnbp−1.080.1487301.150.0982141.120.158070Crlf21.130.1529331.24**0.010318**1.100.290357Cs1.49**0.025871**1.28**0.023492**1.060.583900Cxcr3−1.160.1432451.020.8130421.050.617630Cxcr41.140.1443791.66**0.013166**1.200.141848Adgre1−1.150.4319591.200.273281−1.000.936820Fabp4−1.210.1235791.020.702554−1.140.343194Fasn−1.020.5632221.050.3704871.110.102888Gys11.000.8915181.010.7214901.050.204388Hk2−1.020.5561241.39**0.009742**1.37**0.004545**Ifng−1.420.5181831.760.1475761.540.290151Igf1−1.200.0634151.120.298831−1.000.909747Igf1r1.030.3766091.12**0.009107**1.15**0.000795**Ikbkb1.020.4778481.10**0.031863**1.08**0.013828**Il18r1−1.140.1276501.070.378861−1.080.592830Il1b1.060.5559821.260.1223921.160.340112Il1r1−1.060.5602781.010.9574181.070.683408Il23r−1.130.4266071.160.476194−1.180.546692Il6−1.460.078072−1.210.351666−1.200.426350Insr1.110.1309691.040.5917731.020.833929Irs11.120.3056361.150.2197091.200.177262Irs21.010.775771−1.130.017086−1.14**0.003924**Jak21.030.4244191.23**0.013603**1.27**0.009525**Lep−1.080.3610701.160.211892−1.040.971677Lepr1.110.3770681.59**0.005756**1.300.159982Lipe1.060.2060551.17**0.012267**1.120.252451Lpl−1.210.1244271.100.365642−1.100.808003Lta4h1.020.5316941.13**0.016815**1.11**0.022074**Map2k1−1.060.4458881.100.0788191.060.321980Mapk3−1.020.680433−1.090.096201−1.040.580686Mapk9−1.000.9172901.160.0653111.130.132737Mtor1.030.6844681.24**0.049218**1.190.080924Nampt1.010.8463871.020.732144−1.020.896754Nfkbia−1.090.318262−1.160.065727−1.170.069963Nlrp3−1.060.1267891.240.1265061.010.762575Olr1−1.380.5041191.350.2721881.330.287191Pck1−1.050.5685711.310.0777921.160.490821Pde3b1.020.8253681.030.787814−1.150.190104Pdk21.140.3942471.060.729603−1.230.473372Pdx1−1.010.7100291.240.1002161.040.657469Pik3ca−1.030.399336−1.030.7827511.010.744423Pik3r11.52**0.033282**1.25**0.000901**1.18**0.034911**Ppara−1.020.7924661.210.0806471.020.722852Pparg−1.080.093212−1.030.865268−1.030.216785Ppargc1a1.010.9989041.070.5942091.000.998558Ptpn11.070.2378741.29**0.032159**1.160.189144Pycard1.080.5510261.42**0.036940**1.290.054659Rbp4−1.56**0.007272**1.060.482300−1.070.751105Rela−1.040.5981181.030.6464661.070.279014Retn−1.100.2040381.110.0994511.100.388516Rps6kb1−1.58**0.002976**1.060.1449791.11**0.004902**Scd11.050.8219631.170.4615041.180.410142Serpine1−1.030.8209371.56**0.001029**1.37**0.043504**Slc27a11.010.9293731.040.8059791.130.317341Slc2a41.040.7612401.240.3037591.150.331140Socs3−1.010.8293761.27**0.021130**1.34**0.039503**Srebf11.100.3406751.180.1863471.110.348476Srebf2−1.010.8767721.020.7323511.120.368694Stat3−1.010.6536901.270.0020951.290.001880Tlr41.030.737080−1.050.492373−1.030.761516Tnf−1.220.4801611.330.255783−1.140.607219Tnfrsf1a1.020.4258851.050.3599441.150.089583Tnfrsf1b−1.060.567979−1.220.139907−1.170.161986Ucp11.010.8810831.200.0975311.050.631065Vldlr1.040.699680−1.110.501624−1.130.174714Actb1.010.7776001.33**0.001409**1.33**0.001148**B2m−1.060.258822−1.020.6424301.050.470054Gapdh1.010.8146931.21**0.004777**1.45**0.001734**Gusb1.100.3039101.28**0.021514**1.38**0.038612**Hsp90ab11.030.5460441.19**0.049921**1.21**0.004717**Fig. 2**Number of genes significantly affected by treatment. A.** The graph represents the number of statistically significant (p \< 0.05) up- or down-regulated genes. **B.** Graph represents genes significantly up- or down-regulated within each treatment group, grouped by function.Fig. 2

### 1.3. Role of CAP1 in mediating insulin sensitivity actions of resistin in BNL Cl.2 cells {#sec1.3}

Transfection of the BNL CL.2 cells with CAP1 siRNA resulted in significant change in the expression levels of 24 genes. 23 of these were upregulated (Acsl1, Adipoq, Adipor2, Apoe, Ccr4, Cebpa, Crlf2, Cs, Cxcr4, Hk2, Igflr, Ikbkb, Jak2, Lepr, Lipe, Lta4h, Mtor, Pik3r1, Ptpn1, Pycard, Serpine1, Socs3, and Stat3), and one (Irs2) was downregulated ([Fig. 1](#fig1){ref-type="fig"}A). Divided by function, these genes participate in metabolic pathways (Acsl1, Apoe1, Cebpa, Cs, Hk2, Lepr, and Lipe), insulin signaling (Igf1r, Ikbkb, Mtor, Pik3r1, Ptpn1, Socs3, and Irs2), T2DM (Adipoq, Hk2, Ikbkb, Mtor, Pik3r1, Socs3, and Irs2), adipokine signaling (Adipoq, Adipor2, Ikbkb, Jak2, Lepr, Mtor, Serpine1, Socs3, Stat3, and Irs2), innate immunity (Ikbkb, Pycard, and Irs2), inflammation (ccr4, Cxcr4, Ikbkb, Lta4h, and Pycard), apoptosis (Ikbkb, Jak2, Pycard, Serpine1, Socs3, and Irs2), or are markers of infiltrated leukocytes (Ccr4 and Crlf2) ([Fig. 1](#fig1){ref-type="fig"}, [Fig. 2](#fig2){ref-type="fig"}B).

When CAP1 siRNA-transfected cells were treated with resistin, the expression of 13 genes was significantly affected: 12 genes (Acsl1, Adipor2, Hk2, Igf1r, Ikbkb, Jak2, Lta4h, Pik3r1, Rps6kb1, Serpine1, Socs3, and Stat3) were upregulated, and 1 gene (Irs2) was downregulated ([Table 3](#tbl3){ref-type="table"} and [Fig. 2](#fig2){ref-type="fig"}A). Divided by function, these genes were involved in metabolic pathways (Acsl1 and Hk2), insulin signaling (Igf1r, Ikbkb, Pik3r1, Rps6kb1, Socs3, and Irs2), T2DM (Hk2, Ikbkb, Pik3r1, Socs3, and Irs2), adipokine signaling (Adipor2, Ikbkb, Jak2, Serpine1, Socs3, Stat3, and Irs2), innate immunity (Ikbkb and Irs2), inflammation (Ikbkb and Lta4h), or apoptosis (Ikbkb, Jak2, Rps6kb1, Serpine1, Socs3, and Irs2) ([Table 3](#tbl3){ref-type="table"} and [Fig. 1](#fig1){ref-type="fig"}, [Fig. 2](#fig2){ref-type="fig"}B).

2. Experimental design, materials and methods {#sec2}
=============================================

2.1. Reagents {#sec2.1}
-------------

Mouse recombinant resistin (Sigma-Aldrich, Cat. \# SRP4560) was resuspended in water to a stock concentration of 100 μg/ml and further diluted to 25 μg/ml before cell treatment.

2.2. Cell culture {#sec2.2}
-----------------

BNL CL.2 mouse liver cells were purchased from American Type Culture Collection (ATCC) (Cat. \# TIB-73) and grown in Dulbecco\'s Modified Eagle\'s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (VWR International, Cat. \# 89510--186) and antibiotic/antimycotic solution (Penicillin, Streptomycin, Amphotericin B) (Corning, Cat. \# 30-004-Cl), and incubated at 37 °C with 10% CO~2~.

2.3. Experiment design {#sec2.3}
----------------------

BNL CL.2 cells were seeded in 6-well tissue culture plates with 2 ml tissue culture medium, in a density of 0.5 × 10 [@bib6] cells and grown for one day (to approximately 60% confluency). Resistin treatment was performed by adding 2 μl (25 μg/ml) resistin to the appropriate wells.

2.4. siRNA transfection {#sec2.4}
-----------------------

CAP1 siRNA transfection was performed using Opti-MEM Reduced Serum Medium (Gibco, Cat. \# 31985--070), Lipofectamine RNAiMAX transfection reagent (Invitrogen, Cat. \# 13778--075), and mouse CAP1 Silencer Select siRNA (Life Technologies, Cat. \# 4390771, siRNA ID\# s63297) following manufacturer\'s protocol. Transfection was performed for 6 hours; the cell culture medium was then replaced with complete medium for overnight cell growth.

2.5. RNA extraction and reverse transcription {#sec2.5}
---------------------------------------------

After completing the experiments, the cells were washed one time with ice-cold PBS and RNA was extracted using TRIzol Reagent (Ambion, Cat. \# 15596018), chloroform, and iso-propanol. Total RNA concentration was quantified using NanoDrop One spectrophotometer (Thermo Scientific). All of the samples were normalized to 1 mg/ml of total RNA. Reverse transcriptase (RT) reaction was performed using qScript cDNA SuperMix kit (QuantaBio, Cat. \# 95048). RT reaction was performed using the following conditions: 25 °C/5 min, 42 °C/30 min, 85 °C/5 min, 4 °C/∞. After RT reaction, the cDNA samples were diluted 10 times with water.

2.6. Quantitative RT-PCR array {#sec2.6}
------------------------------

Quantitative RT-PCR array was performed using RT [@bib2] SYBR Green ROX qPCR Mastermix (Qiagen) and RT [@bib2] ProfilerTM PCR Array Mouse Insulin Resistance kit (QIAGEN, Cat. \# PAMM-156ZA). Master mix for each plate consisted of: 1350 μl 2× RT2 SYBR Green Master Mix, 102 μl of cDNA, and 1248 μl of PCR grade water, and 25 μl of it was pipetted into each PCR plate well. Quantitative PCR was performed using the following conditions: hold stage: 50 °C/2 min, 95 °C/10 min; PCR stage: 95 °C/15 sec, 60 °C/1 min (40 cycles); melt curve stage: 60 °C/1 min, 95 °C/1 sec.

2.7. Data analysis {#sec2.7}
------------------

Results were obtained from 4 separate experiments. Data analysis was performed using QIAGEN web-based software (<https://dataanalysis.qiagen.com>). Fold change values were calculated using ΔΔCt method (2ˆ(-ΔΔCt)). p-values were calculated based on Student\'s t-test of the replicate 2ˆ(-ΔCt) values for each gene in the control group and the treatment groups.
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